Equities research analysts expect Lannett Co Inc (NYSE:LCI) to report sales of $162.91 million for the current fiscal quarter, according to Zacks Investment Research. Five analysts have made estimates for Lannett Co’s earnings, with the highest sales estimate coming in at $165.10 million and the lowest estimate coming in at $160.80 million. Lannett Co reported sales of $168.89 million during the same quarter last year, which would suggest a negative year over year growth rate of 3.5%. The business is expected to issue its next quarterly earnings results on Tuesday, August 22nd.

On average, analysts expect that Lannett Co will report full-year sales of $162.91 million for the current fiscal year, with estimates ranging from $659.02 million to $663.30 million. For the next fiscal year, analysts anticipate that the firm will report sales of $650.27 million per share, with estimates ranging from $636.13 million to $677.40 million. Zacks Investment Research’s sales averages are an average based on a survey of research analysts that follow Lannett Co.

Lannett Co (NYSE:LCI) last issued its quarterly earnings data on Tuesday, May 2nd. The company reported $0.77 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.87 by $0.10. The company had revenue of $165.72 million for the quarter, compared to the consensus estimate of $170.28 million. Lannett Co had a negative net margin of 0.41% and a positive return on equity of 22.13%.

LCI has been the subject of a number of recent analyst reports. Zacks Investment Research cut shares of Lannett Co from a “buy” rating to a “hold” rating in a research note on Friday, March 24th. BMO Capital Markets initiated coverage on shares of Lannett Co in a research note on Monday, May 1st. They issued a “market perform” rating and a $29.00 target price for the company. Oppenheimer Holdings, Inc. reiterated a “hold” rating on shares of Lannett Co in a research note on Tuesday, May 2nd. Robert W. Baird reiterated an “outperform” rating and issued a $18.00 target price on shares of Lannett Co in a research note on Wednesday, May 3rd. Finally, ValuEngine cut shares of Lannett Co from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. Six analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Lannett Co presently has an average rating of “Hold” and a consensus target price of $28.33.

A number of hedge funds have recently made changes to their positions in the stock. Comerica Bank boosted its stake in shares of Lannett Co by 5.5% in the fourth quarter. Comerica Bank now owns 31,180 shares of the company’s stock valued at $633,000 after buying an additional 1,634 shares during the last quarter. State Street Corp boosted its stake in shares of Lannett Co by 13.7% in the fourth quarter. State Street Corp now owns 1,186,674 shares of the company’s stock valued at $26,169,000 after buying an additional 142,616 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of Lannett Co by 3.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 966,777 shares of the company’s stock valued at $21,318,000 after buying an additional 28,904 shares during the last quarter. FMR LLC acquired a new stake in shares of Lannett Co during the fourth quarter valued at approximately $7,784,000. Finally, Envestnet Asset Management Inc. boosted its stake in shares of Lannett Co by 39.8% in the fourth quarter. Envestnet Asset Management Inc. now owns 11,037 shares of the company’s stock valued at $244,000 after buying an additional 3,142 shares during the last quarter. Institutional investors and hedge funds own 98.69% of the company’s stock.

Shares of Lannett Co (NYSE LCI) traded down 2.745% on Friday, reaching $20.375. 290,389 shares of the company were exchanged. Lannett Co has a 52 week low of $16.75 and a 52 week high of $39.99. The firm’s 50 day moving average price is $20.02 and its 200 day moving average price is $21.78. The stock’s market capitalization is $758.56 million.

WARNING: This article was reported by American Banking News and is owned by of American Banking News. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/07/07/zacks-analysts-anticipate-lannett-co-inc-lci-will-post-quarterly-sales-of-162-91-million.html.

About Lannett Co

Lannett Company, Inc develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc As of June 30, 2016, the Company’s products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules.

Get a free copy of the Zacks research report on Lannett Co (LCI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Lannett Co (NYSE:LCI)

Receive News & Ratings for Lannett Co Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lannett Co Inc and related companies with MarketBeat.com's FREE daily email newsletter.